Cancer BiologybioRxivPreprint
CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene effect in chronic myeloid leukemia and restores normal hematopoiesis
E. Vuelta, J. L. Ordonez, V. Alonso-Perez…·M. A. Sanchez-Martin
This study uses CRISPR/Cas9 to target and disrupt the BCR/ABL1 oncogene in CML cells, restoring normal hematopoiesis in mouse models and patient-derived xenografts.